Esomeprazole provides improved acid control vs omeprazole in patients with symptoms of GERD

Lind, Tore; Kylebäck, Anders; Rydberg, Lars; Jönsson, Andreas; Andersson, Tommy; Hasselgren, Gunnar; Röhss, Kerstin

doi:10.1016/s0016-5085(00)82139-3

Cited by 6 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Esomeprazole proved to be more effective than omeprazole in maintaining the intra-gastric pH above 4.0, a condition promoting gastric mucosa healing [5].…”

Section: Introductionmentioning

confidence: 99%

Esomeprazole immediate release tablets: Gastric mucosa ex vivo permeation, absorption and antisecretory activity in conscious rats

Benetti

Flammini

Vivo

et al. 2016

Journal of Controlled Release

View full text Add to dashboard Cite

“…Esomeprazole proved to be more effective than omeprazole in maintaining the intra-gastric pH above 4.0, a condition promoting gastric mucosa healing [5].…”

Section: Introductionmentioning

confidence: 99%

Esomeprazole immediate release tablets: Gastric mucosa ex vivo permeation, absorption and antisecretory activity in conscious rats

Benetti

Flammini

Vivo

et al. 2016

Journal of Controlled Release

View full text Add to dashboard Cite

“…11 The S-enantiomer of omeprazole is four times more potent than the R-enantiomer 12 with further work demonstrating that esomeprazole results in more pronounced and consistent acid-suppressive effects compared to omeprazole in humans. 13,14 Area under the curve (AUC) is considered the most important pharmacokinetic determinant of efficacy for proton-pump inhibitors in humans and horses, 15 with a higher AUC expected to be associated with improved outcomes. Studies in people have shown that esomeprazole has a more rapid onset of action, is metabolised by the liver much more slowly, and results in a three to four times higher AUC compared to omeprazole.…”

Section: Introductionmentioning

confidence: 99%

Comparison of oral esomeprazole and oral omeprazole in the treatment of equine squamous gastric disease

Sundra,

Gough,

Rossi

et al. 2023

Equine Veterinary Journal

View full text Add to dashboard Cite

BackgroundOral omeprazole is the accepted treatment for equine squamous gastric disease (ESGD); however, it is not universally effective. Esomeprazole results in more consistent and pronounced acid suppression in men and is more effective than omeprazole in the treatment of oesophageal and gastric disease. Pharmacodynamic and pilot clinical studies have indicated esomeprazole might also be more effective than omeprazole in horses.ObjectivesTo compare the efficacy and safety of oral esomeprazole and omeprazole pastes in the treatment of ESGD and, where present, concurrent equine glandular gastric disease (EGGD).Study designRandomised, single‐blinded controlled trial.MethodsHorses presenting with grade ≥2 ESGD lesions were randomly allocated to receive 4 mg/kg of either a buffered esomeprazole or omeprazole paste orally once daily for 28 days before gastroscopy being repeated within a further 3 days. Videos and images were anonymised and subsequently graded blind by one researcher. The severity of ESGD (and EGGD) lesions before and after treatment, and thereby treatment responses, were compared using univariable logistic regression.ResultsA higher proportion of horses had ESGD healing in response to esomeprazole treatment (63/74, 85%) than with omeprazole treatment (43/73, 59%) (odds ratio [OR]: 4.00, 95% confidence interval [CI]: 1.81, 8.82, p = 0.001). In a subset of horses that had concurrent EGGD, a greater proportion of the horses treated with esomeprazole had lesions ≤grade 1 (esomeprazole 28/51, 55%; omeprazole 6/24, 25%; OR: 3.65, 95% CI: 1.25, 10.71, p = 0.02) Using grade 0 as the benchmark for EGGD healing, the difference remained significant (OR: 4.44, 95% CI: 1.33, 14.85, p = 0.02).Main limitationsIt may not be possible to extrapolate these results to other populations with different signalment or management.ConclusionsOral‐buffered esomeprazole was a more effective treatment for ESGD (and concurrent EGGD) than oral‐buffered omeprazole.

show abstract

“…Esomeprazole (Fig. 1), is a sisomer of omeprazole which is the first drug in its category developed as a single optical isomer 3 .…”

Section: Introductionmentioning

confidence: 99%

Method Development and Validation for the Estimation of Magnesium Content in Esomeprazole Magnesium by Atomic Absorption Spectrophotometer

Kiran¹,

Sundararajan²

2018

Orient. J. Chem

View full text Add to dashboard Cite

A simple, fast and efficient validated method is developed for determination of magnesium content in Esomeprazole-Magnesium by using atomic absorption spectrophotometer (AAS) with 0.2 nm slit width with high speed deuterium (D2) lamp. The read time was set at 3.0 second with 285.2 nm wavelength. The system performance was evaluated by performing the system suitability parameters. The limit of detection and limit of quantification were found to be 0.01 µg/mL and 0.03 µg/mL respectively. The percentages of recovery for low, medium and high spiked concentration levels of magnesium in Esomeprazole-Magnesium were found to be 91.85, 95.02 and 97.89 respectively. With the developed method the magnesium content in Esomeprazole-Magnesium bulk sample was found to be 3.48 % which compliance the United States Pharmacopoeia standard.

show abstract

Esomeprazole provides improved acid control vs omeprazole in patients with symptoms of GERD

Cited by 6 publications

References 0 publications

Esomeprazole immediate release tablets: Gastric mucosa ex vivo permeation, absorption and antisecretory activity in conscious rats

Esomeprazole immediate release tablets: Gastric mucosa ex vivo permeation, absorption and antisecretory activity in conscious rats

Comparison of oral esomeprazole and oral omeprazole in the treatment of equine squamous gastric disease

Method Development and Validation for the Estimation of Magnesium Content in Esomeprazole Magnesium by Atomic Absorption Spectrophotometer

Contact Info

Product

Resources

About